Cinctive Capital Management LP cut its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 49.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 117,421 shares of the company's stock after selling 116,074 shares during the quarter. Cinctive Capital Management LP's holdings in Teva Pharmaceutical Industries were worth $2,588,000 as of its most recent SEC filing.
A number of other hedge funds have also recently bought and sold shares of TEVA. Huntington National Bank lifted its stake in shares of Teva Pharmaceutical Industries by 65.0% in the fourth quarter. Huntington National Bank now owns 5,880 shares of the company's stock valued at $130,000 after buying an additional 2,317 shares during the period. Trexquant Investment LP acquired a new position in Teva Pharmaceutical Industries in the 4th quarter valued at approximately $2,092,000. Headlands Technologies LLC bought a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter worth approximately $132,000. Geode Capital Management LLC grew its holdings in shares of Teva Pharmaceutical Industries by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 9,281,052 shares of the company's stock worth $203,642,000 after purchasing an additional 489,041 shares in the last quarter. Finally, National Bank of Canada FI increased its position in shares of Teva Pharmaceutical Industries by 5,472.4% during the fourth quarter. National Bank of Canada FI now owns 1,019,526 shares of the company's stock valued at $22,470,000 after purchasing an additional 1,001,230 shares during the period. 54.05% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
A number of research firms have weighed in on TEVA. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Friday. Barclays decreased their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a report on Thursday, January 30th. UBS Group lowered their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a research note on Thursday, January 30th. Piper Sandler boosted their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a research note on Friday, January 17th. Finally, Bank of America dropped their price objective on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a research note on Thursday, March 6th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $23.43.
Get Our Latest Stock Report on TEVA
Teva Pharmaceutical Industries Price Performance
Shares of Teva Pharmaceutical Industries stock traded up $0.03 during trading on Monday, reaching $13.83. The company's stock had a trading volume of 13,682,355 shares, compared to its average volume of 9,760,911. The stock has a 50-day moving average price of $16.52 and a two-hundred day moving average price of $18.01. The stock has a market capitalization of $15.68 billion, a P/E ratio of -9.54, a price-to-earnings-growth ratio of 1.44 and a beta of 0.72. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. Teva Pharmaceutical Industries Limited has a one year low of $12.51 and a one year high of $22.80.
Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, topping analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. As a group, sell-side analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.
Teva Pharmaceutical Industries Profile
(
Free Report)
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
Featured Stories
Before you consider Teva Pharmaceutical Industries, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.
While Teva Pharmaceutical Industries currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
